SENTINAL4D
AI models and imaging data tools for biotech and pharmaceutical R&D teams studying cell morphology and drug responses
Highlights
- Young companyFounded 2024
- New on EvolcAdded 2026-11-09
About SENTINAL4D
Sentinal4D develops AI models and data tools that interpret biological motion and cell morphology from 3D and 4D imaging. Its products support analysis of drug response, cell fate, pathway activity, mechanism of action, and toxicity, and include a SaaS platform and an annotated library of cancer cell movies.
The products are designed for biological and pharmaceutical research and development. The company is registered in London and was founded in 2024.
Product: AI models, an integrated SaaS platform, and an annotated library for analyzing cell morphology and biological motion in imaging data.
Jobs at SENTINAL4D
More biotech & pharma companies
Sequoia Genetics
Human genetics research and analysis for pharma, biotech, investors, and academic institutions developing medicinesYoung companyNew on EvolcSeren Plus
Wholesale supplier of prescription medicines and aesthetic products to pharmacies and clinics across the UKNew on EvolcShafi Consultancy
Clinical trial statistical programming and data services for pharmaceutical companies and contract research organizationsNew on EvolcSimplex Molecular
Molecular biology R&D, assay development and testing for research teams and businessesYoung companyNew on EvolcSisaf
RNA drug-delivery platform licensed to pharma partners, with a research reagent for labs plannedNew on EvolcSitala Bio
Develops medicines targeting harmful inflammation for patients with neurodegenerative and inflammatory diseasesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- FramerHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.